Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma - Brighton, Timothy; Khot, Amit; Harrison, Simon J.; Ghez, David; Weiss, Brendan M.; Kirsch, Andreas; Magen, Hila; Gironella, Mercedes; Oriol, Albert; Streetly, Matthew; Kranenburg, Britte; Qin, Xiang; et al. (Clinical cancer research, 2019)
Gesehen am 30.08.2019